While GLP1 receptor agonists have long been recognized for their glucose-lowering and weight-loss effects, they now offer potential for improving liver outcomes, especially in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) or its more advanced form, metabolic dysfunction-associated steatohepatitis (MASH)
The areas that warrant attention are overlapping GI side effects early in treatment, mood monitoring as your body changes, and making sure both prescribers are in the loop
Premium Quality: Proudly made in the USA using the absolute finest locally and globally sourced ingredients in an FDA-certified facility
Lithium's effects on cyclic AMP, membrane transport and cholinergic mechanisms
insist on certificates of analysis (CoA) verifying purity (typically 98% or higher), peptide sequence confirmation via HPLC, and low levels of heavy metals and endotoxins